Lipoproteins and cardiovascular risk-from genetics to CHD prevention.
Dyslipidemia is said to be present when lipid or lipoprotein levels lie within a range which is known from epidemiological studies to be associated with secondary complications, in particular atherosclerosis of the coronary arteries, or when a lipid or lipoprotein grossly deviates from the norm as in abetalipoproteinemia, hypobetalipoproteinemia or the HDL deficiency syndromes. In most cases, dyslipidemia is due not to a single genetic or environmental factor, but to a combination of the effects of several genes of small effect (polygenes) and environment. In other cases, however, dyslipidemia is caused by a mutation in a single gene of large effect. In such cases, the extent and nature of the phenotype depends primarily on the identity of the gene involved, but is also modulated to an important degree by the nature of the mutation and the genetic and environmental background against which this mutation occurs. In addition, many cases of hyperlipidemia are secondary to other disorders such as hypothyroidism or renal dysfunction. Such disorders may also unmask or exacerbate a genetic lipoprotein disorder. Examples of the latter are the unmasking of type III hyperlipidemia by diabetes mellitus or the exacerbation of familial hypercholesterolemia by hypothyroidism.
Cullen
P
P
Institute of Arteriosclerosis Research, University of Münster, Germany.
Funke
H
H
Schulte
H
H
Assmann
G
G
D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000235:genetics* / Q000517:prevention & control; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000628:therapy; D008074:Lipoproteins / Q000097:blood*; D012307:Risk Factors
D008074:Lipoproteins